Drug profile · INN
erythromycin stearate
ERYTHROMYCIN STEARATE
erythromycin stearate (ERYTHROMYCIN STEARATE) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — erythromycin stearate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
erythromycin stearate (ERYTHROMYCIN STEARATE) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial 70S ribosome inhibitor
Primary target: Bacterial 70S ribosome
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is erythromycin stearate?
erythromycin stearate (ERYTHROMYCIN STEARATE) is a bacterial 70s ribosome inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for erythromycin stearate?
ERYTHROMYCIN STEARATE is a marketed brand name for erythromycin stearate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of erythromycin stearate?
erythromycin stearate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.